HUE029670T2 - Preparations containing pneumococcal antigens - Google Patents
Preparations containing pneumococcal antigens Download PDFInfo
- Publication number
- HUE029670T2 HUE029670T2 HUE12197549A HUE12197549A HUE029670T2 HU E029670 T2 HUE029670 T2 HU E029670T2 HU E12197549 A HUE12197549 A HU E12197549A HU E12197549 A HUE12197549 A HU E12197549A HU E029670 T2 HUE029670 T2 HU E029670T2
- Authority
- HU
- Hungary
- Prior art keywords
- seq
- antigen
- amino acid
- acid sequence
- ahol ahol
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims 46
- 102000036639 antigens Human genes 0.000 title claims 46
- 108091007433 antigens Proteins 0.000 title claims 46
- 239000000203 mixture Substances 0.000 title claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 239000002253 acid Substances 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 10
- 235000001014 amino acid Nutrition 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 7
- 150000001412 amines Chemical class 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 241000283073 Equus caballus Species 0.000 claims 2
- 235000019788 craving Nutrition 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- CMFIWMWBTZQTQH-IDTAVKCVSA-N 9-[(2r,3r,4s,5s)-3,4-dihydroxy-5-(2-methylpropylsulfanylmethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC(C)C)O[C@H]1N1C(NC=NC2=O)=C2N=C1 CMFIWMWBTZQTQH-IDTAVKCVSA-N 0.000 claims 1
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 241001417527 Pempheridae Species 0.000 claims 1
- 206010040844 Skin exfoliation Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 150000001345 alkine derivatives Chemical class 0.000 claims 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 230000003460 anti-nuclear Effects 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002131 composite material Substances 0.000 claims 1
- 230000035618 desquamation Effects 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 208000001848 dysentery Diseases 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- IXSZQYVWNJNRAL-UHFFFAOYSA-N etoxazole Chemical compound CCOC1=CC(C(C)(C)C)=CC=C1C1N=C(C=2C(=CC=CC=2F)F)OC1 IXSZQYVWNJNRAL-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012133 immunoprecipitate Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 150000004682 monohydrates Chemical class 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000013618 particulate matter Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000001012 protector Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000005070 sphincter Anatomy 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229960000814 tetanus toxoid Drugs 0.000 claims 1
- 230000002024 thermoprotective effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0714963.6A GB0714963D0 (en) | 2007-08-01 | 2007-08-01 | Compositions comprising antigens |
| US96686607P | 2007-08-29 | 2007-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE029670T2 true HUE029670T2 (en) | 2017-03-28 |
Family
ID=38529101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12197549A HUE029670T2 (en) | 2007-08-01 | 2008-08-01 | Preparations containing pneumococcal antigens |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20110243976A1 (enExample) |
| EP (2) | EP2197484A2 (enExample) |
| JP (2) | JP2010535025A (enExample) |
| CN (2) | CN104001165B (enExample) |
| AP (1) | AP2010005173A0 (enExample) |
| AU (1) | AU2008281438A1 (enExample) |
| BR (1) | BRPI0813892A2 (enExample) |
| CA (1) | CA2695169A1 (enExample) |
| CO (1) | CO6260103A2 (enExample) |
| CY (1) | CY1117689T1 (enExample) |
| DK (1) | DK2572726T3 (enExample) |
| EA (1) | EA018137B1 (enExample) |
| ES (1) | ES2580957T3 (enExample) |
| GB (1) | GB0714963D0 (enExample) |
| HR (1) | HRP20160685T1 (enExample) |
| HU (1) | HUE029670T2 (enExample) |
| PL (1) | PL2572726T3 (enExample) |
| PT (1) | PT2572726T (enExample) |
| SI (1) | SI2572726T1 (enExample) |
| WO (1) | WO2009016515A2 (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| WO2007000341A2 (en) | 2005-06-27 | 2007-01-04 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| US8241643B2 (en) | 2008-03-17 | 2012-08-14 | Intercell Ag | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
| ATE523204T1 (de) | 2009-02-16 | 2011-09-15 | Karlsruher Inst Technologie | Cd44v6-peptide als bakterielle infektionsinhibitoren |
| CA2764022A1 (en) * | 2009-06-01 | 2010-12-09 | Novartis Ag | Combinations of pneumococcal rrgb clades |
| IN2012DN00791A (enExample) * | 2009-06-29 | 2015-06-26 | Genocea Biosciences Inc | |
| CA2773637A1 (en) * | 2009-09-10 | 2011-03-17 | Novartis Ag | Combination vaccines against respiratory tract diseases |
| CN102939105B (zh) * | 2009-12-22 | 2016-11-16 | 赛诺菲巴斯德有限公司 | 免疫原性组合物和相关的方法 |
| JP2013525271A (ja) | 2010-03-12 | 2013-06-20 | チルドレンズ メディカル センター コーポレーション | 免疫原およびそのスクリーニング方法 |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| EP3243526B1 (en) | 2010-07-06 | 2019-11-27 | GlaxoSmithKline Biologicals S.A. | Delivery of rna to trigger multiple immune pathways |
| PT2591114T (pt) | 2010-07-06 | 2016-08-02 | Glaxosmithkline Biologicals Sa | Imunização de mamíferos de grande porte com doses baixas de arn |
| HRP20161352T1 (hr) | 2010-07-06 | 2016-12-02 | Glaxosmithkline Biologicals Sa | Čestice nalik na virione za unos samoreplicirajućih molekula rna |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| EP2590626B1 (en) | 2010-07-06 | 2015-10-28 | GlaxoSmithKline Biologicals SA | Liposomes with lipids having an advantageous pka-value for rna delivery |
| US9770463B2 (en) | 2010-07-06 | 2017-09-26 | Glaxosmithkline Biologicals Sa | Delivery of RNA to different cell types |
| SI2608805T2 (sl) | 2010-08-23 | 2025-09-30 | Wyeth Llc | Stabilne formulacije antigenov rLP2086 neisserie meningitidis |
| PL4066857T3 (pl) | 2010-08-31 | 2023-03-20 | Glaxosmithkline Biologicals Sa | Pegylowane liposomy do dostarczania rna kodującego immunogen |
| CA2809863A1 (en) | 2010-08-31 | 2012-03-08 | Novartis Ag | Lipids suitable for liposomal delivery of protein-coding rna |
| BR112013005329A2 (pt) | 2010-09-10 | 2017-05-02 | Wyeth Llc | variantes não lipidadas de antígenos orf2086 de neisseria meningitidis |
| CA2814386C (en) | 2010-10-11 | 2019-08-20 | Novartis Ag | Antigen delivery platforms |
| WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
| JP6126993B2 (ja) | 2011-01-20 | 2017-05-10 | ジェノセア バイオサイエンシーズ， インコーポレイテッド | 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対するワクチン及び組成物 |
| WO2012149268A1 (en) | 2011-04-29 | 2012-11-01 | Selecta Biociences, Inc. | Tolerogenic synthetic nanocarriers for allergy therapy |
| CA2835630A1 (en) | 2011-05-11 | 2012-11-15 | Richard Malley | Modified biotin-binding protein, fusion proteins thereof and applications |
| CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| CN103764121A (zh) | 2011-07-06 | 2014-04-30 | 诺华股份有限公司 | 用于递送rna分子的具有有用n:p比的脂质体 |
| TR201900264T4 (tr) | 2011-08-31 | 2019-02-21 | Glaxosmithkline Biologicals Sa | İmmünojen şifreleyici rna'nın verilmesi için pegile edilmiş lipozomlar. |
| EP2764093B1 (en) * | 2011-10-05 | 2018-04-18 | The Rockefeller University | Dimeric bacteriophage lysins |
| AU2012335208B2 (en) * | 2011-11-07 | 2017-08-31 | Glaxosmithkline Biologicals S.A. | Carrier molecule comprising a spr0096 and a spr2021 antigen |
| CN104519910B (zh) | 2012-03-07 | 2017-05-03 | 诺华股份有限公司 | 肺炎链球菌抗原的含佐剂制剂 |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| MX2018011291A (es) | 2012-03-09 | 2023-01-31 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
| KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| MX363529B (es) | 2012-09-18 | 2019-03-27 | Novartis Ag | Vesículas de membrana externa. |
| KR20140075196A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| EP2953638B1 (en) | 2013-02-07 | 2023-07-05 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
| AU2014224205C1 (en) | 2013-03-08 | 2019-04-04 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| WO2014136064A2 (en) | 2013-03-08 | 2014-09-12 | Pfizer Inc. | Immunogenic fusion polypeptides |
| US10357483B2 (en) | 2013-05-03 | 2019-07-23 | Selecta Biosciences, Inc. | Methods comprising dosing combinations for reducing undesired humoral immune responses |
| BR112016004463A2 (pt) | 2013-09-08 | 2017-10-17 | Pfizer | composições de neisseria meningitidis e métodos das mesmas |
| US10426737B2 (en) | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| WO2015095340A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| ES2949172T3 (es) | 2014-07-16 | 2023-09-26 | Novartis Ag | Método de encapsulamiento de un ácido nucleico en un hospedante de nanopartículas lipídicas |
| ES2969956T3 (es) | 2014-09-05 | 2024-05-23 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| AU2015311707B2 (en) | 2014-09-07 | 2021-12-09 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
| US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| WO2016132294A1 (en) | 2015-02-19 | 2016-08-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EP3061826A1 (en) | 2015-02-27 | 2016-08-31 | Novartis AG | Flavivirus replicons |
| CN104844712B (zh) * | 2015-04-03 | 2019-06-28 | 长春百克生物科技股份公司 | 肺炎链球菌蛋白抗原及其制备方法和应用 |
| GB201509782D0 (en) * | 2015-06-05 | 2015-07-22 | Isis Innovation | Methods and products for fusion protein synthesis |
| TWI745323B (zh) | 2015-12-10 | 2021-11-11 | 加拿大國家研究委員會 | 脂化之肺炎鏈球菌抗原組合物、製備方法及用途 |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| AU2018215585B2 (en) * | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| CA3055936A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| CN110730670A (zh) | 2017-03-28 | 2020-01-24 | 儿童医疗中心有限公司 | 基于多抗原提呈系统(maps)的金黄色葡萄球菌疫苗、免疫原性组合物以及它们的用途 |
| GB201705750D0 (en) | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | Peptide ligase and use therof |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| BR112019026192B1 (pt) | 2017-06-10 | 2022-05-10 | Inventprise, Llc | Vacinas de conjugado multivalente com polissacarídeos de conjugado bivalente ou multivalente que fornecem imunogenicidade e avidez melhoradas |
| TWI850197B (zh) | 2017-06-23 | 2024-08-01 | 美國馬里蘭大學巴爾的摩分校 | 免疫原性組成物 |
| KR20210088535A (ko) | 2018-09-12 | 2021-07-14 | 더 칠드런스 메디칼 센터 코포레이션 | 폐렴구균 융합 단백질 백신 |
| SG11202102007UA (en) | 2018-09-12 | 2021-03-30 | Affinivax Inc | Multivalent pneumococcal vaccines |
| US20230066762A1 (en) * | 2019-08-05 | 2023-03-02 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| MX2022003682A (es) | 2019-09-27 | 2022-04-25 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
| US12053515B2 (en) | 2020-08-10 | 2024-08-06 | Inventprise, Inc. | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F |
| IL301890A (en) | 2020-10-14 | 2023-06-01 | George Mason Res Foundation Inc | Ionizable lipids and methods of manufacture and use thereof |
| US20240350410A1 (en) | 2021-08-16 | 2024-10-24 | Glaxosmithkline Biologicals Sa | Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof |
| WO2023021421A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Low-dose lyophilized rna vaccines and methods for preparing and using the same |
| WO2023039223A1 (en) | 2021-09-09 | 2023-03-16 | Affinivax, Inc. | Multivalent pneumococcal vaccines |
| CN114507658B (zh) * | 2022-04-02 | 2022-07-05 | 深圳瑞德林生物技术有限公司 | 酶共表达系统及其在合成唾液酸的应用 |
| WO2023236878A1 (zh) * | 2022-06-07 | 2023-12-14 | 北京大学第一医院 | 包含IgA蛋白酶截短体的融合蛋白及其用途 |
| WO2024006863A1 (en) | 2022-06-30 | 2024-01-04 | Precision NanoSystems ULC | Lipid nanoparticle formulations for vaccines |
| CN116063548B (zh) * | 2022-07-08 | 2025-06-10 | 中国人民解放军陆军军医大学 | 一种融合蛋白KP-Ag1及其用作肺炎克雷伯菌疫苗抗原的应用 |
| GB202303019D0 (en) | 2023-03-01 | 2023-04-12 | Glaxosmithkline Biologicals Sa | Method of lyophilisation |
| CN116333063B (zh) * | 2023-04-21 | 2024-03-12 | 华中农业大学 | 胸膜肺炎放线杆菌的三个候选抗原及其应用 |
| WO2025005990A1 (en) | 2023-06-28 | 2025-01-02 | Global Life Sciences Solutions Canada Ulc | Lipid nanoparticle formulations for cell therapy and related methods |
| GB202311382D0 (en) | 2023-07-25 | 2023-09-06 | Glaxosmithkline Biologicals Sa | Lyophilised compostion |
Family Cites Families (188)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| US4315919A (en) * | 1980-10-06 | 1982-02-16 | Edward Shanbrom | Depyrogenation process |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
| US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
| US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
| US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
| AU627226B2 (en) | 1988-08-25 | 1992-08-20 | Liposome Company, Inc., The | Influenza vaccine and novel adjuvants |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
| EP0449856B1 (en) | 1988-12-16 | 2001-09-12 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Pneumolysin mutants and pneumococcal vaccines made therefrom |
| US6716432B1 (en) | 1988-12-16 | 2004-04-06 | James Cleland Paton | Pneumolysin mutants and pneumococcal vaccines made therefrom |
| ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
| EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
| JP3250802B2 (ja) | 1989-03-21 | 2002-01-28 | バイカル・インコーポレイテッド | 脊椎動物における外因性ポリヌクレオチド配列の発現 |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5334379A (en) | 1989-07-14 | 1994-08-02 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| CA2066053C (en) | 1989-08-18 | 2001-12-11 | Harry E. Gruber | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| ZA911974B (en) | 1990-03-21 | 1994-08-22 | Res Dev Foundation | Heterovesicular liposomes |
| US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| US5149655A (en) | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
| GB2276169A (en) | 1990-07-05 | 1994-09-21 | Celltech Ltd | Antibodies specific for carcinoembryonic antigen |
| IL98715A0 (en) | 1990-08-13 | 1992-07-15 | American Cyanamid Co | Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines |
| DK0563278T3 (da) | 1990-12-20 | 2000-08-21 | Dana Farber Cancer Inst Inc | Regulering af geneekspression med ioniserende stråling |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| WO1992015582A1 (en) | 1991-03-01 | 1992-09-17 | Minnesota Mining And Manufacturing Company | 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES |
| DK0648271T3 (da) | 1991-08-20 | 2003-07-21 | Us Gov Health & Human Serv | Adenovirusmedieret overførsel af gener til mave-/tarmkanal |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| UA40597C2 (uk) | 1992-06-25 | 2001-08-15 | Смітклайн Бічем Байолоджікалс С.А. | Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| EP1175912A1 (en) | 1993-03-23 | 2002-01-30 | SmithKline Beecham Biologics SA | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
| WO1994023697A1 (en) | 1993-04-22 | 1994-10-27 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| DE69434486T2 (de) | 1993-06-24 | 2006-07-06 | Advec Inc. | Adenovirus vektoren für gentherapie |
| ES2149276T3 (es) | 1993-07-15 | 2000-11-01 | Minnesota Mining & Mfg | Imidazo(4,5-c)piridin-4-aminas. |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| EP0814154B1 (en) | 1993-09-15 | 2009-07-29 | Novartis Vaccines and Diagnostics, Inc. | Recombinant alphavirus vectors |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| DE69434594T2 (de) | 1993-10-25 | 2006-09-21 | Canji, Inc., San Diego | Rekombinante adenoviren-vektor und verfahren zur verwendung |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| KR100241300B1 (ko) | 1993-11-16 | 2000-03-02 | Sheldon A. Schaffer | 활성물질의 조절된 방출성을 갖는 소포 |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| AU2585395A (en) | 1994-05-09 | 1995-11-29 | Chiron Corporation | Retroviral vectors having a reduced recombination rate |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| US20020028215A1 (en) * | 1999-08-09 | 2002-03-07 | Jagath L. Kadurugamuwa | Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same |
| ATE424463T1 (de) | 1996-05-06 | 2009-03-15 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
| AU5194598A (en) | 1996-10-31 | 1998-05-22 | Human Genome Sciences, Inc. | (streptococcus pneumoniae) antigens and vaccines |
| WO1998040100A1 (en) | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| KR100619350B1 (ko) | 1997-07-21 | 2006-09-05 | 박스터 헬쓰케어 에스.에이. | 변형 면역성 뉴멀리신 백신조성물 |
| DE69815692T2 (de) | 1997-09-05 | 2004-04-29 | Glaxosmithkline Biologicals S.A. | Öl in wasser emulsionen mit saponinen |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| EP1053015A2 (en) | 1998-02-12 | 2000-11-22 | American Cyanamid Company | Pneumococcal and meningococcal vaccines formulated with interleukin-12 |
| US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| AU746163B2 (en) | 1998-04-09 | 2002-04-18 | Smithkline Beecham Biologicals (Sa) | Adjuvant compositions |
| JP2002516251A (ja) | 1998-04-23 | 2002-06-04 | ユーエイビー リサーチ ファンデーション | 肺炎球菌表面プロテインＣ（ＰｓｐＣ）のエピトープ領域およびその菌株選択、ならびにそのための使用法 |
| KR100682154B1 (ko) | 1998-05-07 | 2007-02-12 | 코릭사 코포레이션 | 아쥬번트 조성물 및 그의 사용방법 |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| EP1144640A3 (en) | 1998-07-27 | 2001-11-28 | Microbial Technics Limited | Nucleic acids and proteins from streptococcus pneumoniae |
| JP2002531055A (ja) | 1998-07-27 | 2002-09-24 | マイクロビアル テクニクス リミティッド | 肺炎連鎖球菌のタンパク質及び核酸分子 |
| US20030134407A1 (en) * | 1998-07-27 | 2003-07-17 | Le Page Richard William Falla | Nucleic acids and proteins from Streptococcus pneumoniae |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| CN1263510C (zh) | 1998-08-19 | 2006-07-12 | 巴克斯特健康护理股份有限公司 | 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用 |
| CA2773698C (en) | 1998-10-16 | 2015-05-19 | Glaxosmithkline Biologicals S.A. | Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof |
| AU1626199A (en) | 1998-12-04 | 2000-06-26 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A vi-repa conjugate vaccine for immunization against salmonella typhi |
| ES2322306T3 (es) | 1998-12-21 | 2009-06-18 | Medimmune, Inc. | Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas. |
| US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| MXPA01007895A (es) | 1999-02-03 | 2003-07-21 | Biosante Pharmaceuticals Inc | Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos. |
| MY125202A (en) | 1999-03-19 | 2006-07-31 | Smithkline Beecham Biologicals S A | Vaccine |
| CN1198932C (zh) | 1999-03-26 | 2005-04-27 | 科特克斯(Om)有限公司 | 肺炎链球菌抗原 |
| WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| WO2000076540A2 (en) | 1999-06-10 | 2000-12-21 | Med Immune, Inc. | Streptococcus pneumoniae proteins and vaccines |
| EP1075841A1 (en) | 1999-08-13 | 2001-02-14 | Erasmus Universiteit Rotterdam | Pneumococcal vaccines |
| HK1046861A1 (zh) | 1999-09-24 | 2003-01-30 | Smithkline Beecham Biologicals S.A. | 包括聚氧乙烯烷基酯或者醚以及至少一種非離子表面活性劑的佐劑 |
| IL148672A0 (en) | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| AP2006003503A0 (en) | 1999-09-25 | 2006-02-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
| AU3108001A (en) | 2000-01-20 | 2001-12-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing a th2 immune response |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| EP1278856A2 (en) | 2000-04-27 | 2003-01-29 | Medimmune, Inc. | Immunogenic pneumococcal protein and vaccine compositions thereof |
| AU2001287645A1 (en) | 2000-07-20 | 2002-02-05 | Hansa Medical Ab | Fh-binding protein of streptococcus pneumiae |
| ES2334641T3 (es) | 2000-09-01 | 2010-03-15 | Novartis Vaccines And Diagnostics, Inc. | Derivados aza heterociclicos y su uso terapeutico. |
| NZ524717A (en) | 2000-09-11 | 2004-09-24 | Chiron Corp | Quinolinone derivatives |
| GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| JP2004509970A (ja) | 2000-09-26 | 2004-04-02 | ハイブリドン・インコーポレイテッド | 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節 |
| EP1330473A2 (en) | 2000-10-26 | 2003-07-30 | Imperial College Innovations Limited | Streptococcal genes |
| US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
| US6664260B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Heterocyclic ether substituted imidazoquinolines |
| US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
| UA75622C2 (en) | 2000-12-08 | 2006-05-15 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon |
| US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| US6660735B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Urea substituted imidazoquinoline ethers |
| US6660747B2 (en) | 2000-12-08 | 2003-12-09 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
| GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| GB0108079D0 (en) | 2001-03-30 | 2001-05-23 | Microbial Technics Ltd | Protein |
| WO2002091998A2 (en) | 2001-05-11 | 2002-11-21 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| WO2003024480A2 (en) | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| CN1599623B (zh) | 2001-09-14 | 2011-05-11 | 赛托斯生物技术公司 | 免疫刺激物向病毒样颗粒内的包装:制备方法与用途 |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| GEP20074099B (en) | 2001-11-27 | 2007-05-10 | Anadys Pharmaceuticals Inc | 3-β-D-RIBOFURANO-SYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF |
| US7321033B2 (en) | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
| US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| EA007987B1 (ru) | 2002-03-29 | 2007-02-27 | Чирон Корпорейшн | Замещённые бензазолы и их применение в качестве ингибиторов киназы raf |
| EP2275125A3 (en) | 2002-04-02 | 2011-03-09 | Ben Gurion University Of The Negev Research And Development Authority | Protein-based streptococcus pneumoniae vaccines |
| WO2003101949A2 (en) | 2002-05-29 | 2003-12-11 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
| PL374534A1 (en) | 2002-06-11 | 2005-10-31 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions |
| JP2005533057A (ja) | 2002-06-13 | 2005-11-04 | ニューヨーク・ユニバーシティ | 合成ｃ−糖脂質、ならびに癌、感染性疾患および自己免疫疾患を処置するための合成ｃ−糖脂質の使用 |
| US7250443B2 (en) | 2002-08-23 | 2007-07-31 | Chiron Corporation | Pyrrole based inhibitors of glycogen synthase kinase 3 |
| WO2004020609A2 (en) * | 2002-08-30 | 2004-03-11 | Tufts University | Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection |
| EP1558280B1 (en) | 2002-11-07 | 2014-01-08 | Synergy America, Inc. | Compositions and methods for treating or preventing pneumococcal infection |
| US7521062B2 (en) | 2002-12-27 | 2009-04-21 | Novartis Vaccines & Diagnostics, Inc. | Thiosemicarbazones as anti-virals and immunopotentiators |
| ES2391770T3 (es) | 2003-01-21 | 2012-11-29 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos de triptantrina para la potenciación inmune |
| GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
| US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
| EP2311991A1 (en) * | 2003-04-15 | 2011-04-20 | Intercell AG | S. pneumoniae antigens |
| RU2236257C1 (ru) | 2003-09-15 | 2004-09-20 | Косяков Константин Сергеевич | Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами |
| US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
| WO2005063283A1 (en) | 2003-12-31 | 2005-07-14 | Sungkyunkwan University | Vaccine comprising recombinant clpp protein of streptococcus pneumoniae |
| CA2560969A1 (en) | 2004-03-31 | 2005-11-03 | New York University | Novel synthetic c-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases |
| DK1742659T3 (da) | 2004-04-05 | 2013-06-03 | Zoetis P Llc | Mikrofluidiserede olie-i-vand-emulsioner og vaccinesammensætninger |
| GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
| CA2597489A1 (en) * | 2005-02-11 | 2006-08-17 | Ace Biosciences A/S | Surface-located streptococcus pneumoniae polypeptides |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US20060228369A1 (en) | 2005-04-11 | 2006-10-12 | Program For Appropriate Technology In Health | Stabilization and preservation of temperature-sensitive vaccines |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| MX2007015105A (es) * | 2005-06-01 | 2008-03-18 | Variation Biotechnologies Inc | Formulacion de vacuna de influenza a base de peptido. |
| WO2007000341A2 (en) | 2005-06-27 | 2007-01-04 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| HUE032903T2 (hu) | 2005-12-22 | 2017-11-28 | Glaxosmithkline Biologicals Sa | Streptococcus pneumoniae kapszulárispoliszacharid-konjugátumok |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| AU2007237133A1 (en) | 2006-02-17 | 2007-10-18 | Novartis Ag | Purification of bacterial antigens |
| DK2004225T3 (da) * | 2006-03-22 | 2012-08-06 | Novartis Ag | Programmer for vaccination med meningocockonjugater |
| KR101151202B1 (ko) | 2006-10-12 | 2012-06-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 수중유 에멀젼 애주번트를 포함하는 백신 |
| EP1923069A1 (en) | 2006-11-20 | 2008-05-21 | Intercell AG | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
| AU2012335208B2 (en) * | 2011-11-07 | 2017-08-31 | Glaxosmithkline Biologicals S.A. | Carrier molecule comprising a spr0096 and a spr2021 antigen |
-
2007
- 2007-08-01 GB GBGB0714963.6A patent/GB0714963D0/en not_active Ceased
-
2008
- 2008-08-01 PT PT121975494T patent/PT2572726T/pt unknown
- 2008-08-01 EA EA201070200A patent/EA018137B1/ru not_active IP Right Cessation
- 2008-08-01 CN CN201410192895.3A patent/CN104001165B/zh not_active Expired - Fee Related
- 2008-08-01 ES ES12197549.4T patent/ES2580957T3/es active Active
- 2008-08-01 DK DK12197549.4T patent/DK2572726T3/en active
- 2008-08-01 US US12/733,010 patent/US20110243976A1/en not_active Abandoned
- 2008-08-01 BR BRPI0813892A patent/BRPI0813892A2/pt not_active IP Right Cessation
- 2008-08-01 AU AU2008281438A patent/AU2008281438A1/en not_active Abandoned
- 2008-08-01 SI SI200831646A patent/SI2572726T1/sl unknown
- 2008-08-01 JP JP2010518777A patent/JP2010535025A/ja active Pending
- 2008-08-01 HU HUE12197549A patent/HUE029670T2/en unknown
- 2008-08-01 CA CA2695169A patent/CA2695169A1/en not_active Abandoned
- 2008-08-01 WO PCT/IB2008/002866 patent/WO2009016515A2/en not_active Ceased
- 2008-08-01 EP EP08826694A patent/EP2197484A2/en not_active Withdrawn
- 2008-08-01 CN CN200880108017A patent/CN101801409A/zh active Pending
- 2008-08-01 AP AP2010005173A patent/AP2010005173A0/en unknown
- 2008-08-01 EP EP12197549.4A patent/EP2572726B1/en active Active
- 2008-08-01 PL PL12197549.4T patent/PL2572726T3/pl unknown
-
2010
- 2010-03-01 CO CO10023973A patent/CO6260103A2/es not_active Application Discontinuation
-
2013
- 2013-11-06 JP JP2013230378A patent/JP5838193B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-06 US US14/298,764 patent/US20140348868A1/en not_active Abandoned
-
2016
- 2016-06-16 HR HRP20160685TT patent/HRP20160685T1/hr unknown
- 2016-06-28 CY CY20161100580T patent/CY1117689T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2572726A1 (en) | 2013-03-27 |
| US20110243976A1 (en) | 2011-10-06 |
| HRP20160685T1 (hr) | 2016-07-15 |
| WO2009016515A2 (en) | 2009-02-05 |
| GB0714963D0 (en) | 2007-09-12 |
| JP5838193B2 (ja) | 2016-01-06 |
| DK2572726T3 (en) | 2016-07-04 |
| SI2572726T1 (sl) | 2016-08-31 |
| CY1117689T1 (el) | 2017-05-17 |
| CN101801409A (zh) | 2010-08-11 |
| CO6260103A2 (es) | 2011-03-22 |
| PT2572726T (pt) | 2016-08-05 |
| PL2572726T3 (pl) | 2016-12-30 |
| JP2010535025A (ja) | 2010-11-18 |
| CA2695169A1 (en) | 2009-02-05 |
| US20140348868A1 (en) | 2014-11-27 |
| EP2197484A2 (en) | 2010-06-23 |
| BRPI0813892A2 (pt) | 2017-05-09 |
| EP2572726B1 (en) | 2016-05-04 |
| EA201070200A1 (ru) | 2010-08-30 |
| EA018137B1 (ru) | 2013-05-30 |
| AU2008281438A1 (en) | 2009-02-05 |
| ES2580957T3 (es) | 2016-08-30 |
| WO2009016515A3 (en) | 2009-08-13 |
| AP2010005173A0 (en) | 2010-02-28 |
| CN104001165A (zh) | 2014-08-27 |
| CN104001165B (zh) | 2018-08-14 |
| JP2014034578A (ja) | 2014-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2572726T3 (en) | Compositions comprising pneumococcal antigens | |
| US8609106B2 (en) | Combinations of pneumococcal RrgB clades | |
| AU2011219524B2 (en) | Immunogenic proteins and compositions | |
| EP2552477B1 (en) | Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae | |
| EP2331120A1 (en) | Factor h binding protein immunogens | |
| US20200360504A1 (en) | Pseudomonas antigens and antigen combinations | |
| WO2012072769A1 (en) | Pneumococcal rrgb epitopes and clade combinations |